STAT+: Pharmalittle: ALS Association and its chapters battle over money and priorities; eye drops recalled over links to drug-resistant infections
And so, another working week will soon draw to a close. Not a moment too…
Category: Pharmalot
STAT+: Leading ALS advocacy group roiled by infighting over money and priorities
A blistering battle has broken out between the ALS Association and more than a dozen…
STAT+: Pharmalittle: GSK CEO warns U.K. pharma industry is at a ‘tipping point’; Gavi tussles with vaccine makers over refunds
Top of the morning to you. And a fine one it is. Sunny skies and…
STAT+: Pharmalittle: Pfizer projects lower revenue from Covid-19 products; Medicare eyes policy for paying less for accelerated-approval drugs
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Pharmalittle: Amgen pricing for Humira biosimilar may not help patients; pharma wins court battle over drug discount program
Hello, everyone, and how are you this morning? We are just fine, thank you, although…
STAT+: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients
Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited pricing for its…
STAT+: U.K. lawmakers urge Pfizer not to raise the price of its Covid-19 vaccine
Several U.K. lawmakers have asked Pfizer not to raise the price of its Covid-19 vaccine,…
STAT+: Pharma wins a key round in a court battle with hospitals over a drug discount program
In a victory for the pharmaceutical industry, a federal appeals court ruled drug companies have…
STAT+: Pharmalittle: Pfizer is scolded by U.K. industry group over CEO’s remarks on vaccination; Amgen to lay off 300 U.S. employees
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: ‘A classic case’: A legal expert on why lawsuits challenging abortion pill restrictions may succeed
A pair of lawsuits was filed last week challenging restrictions on access to abortion pills…
STAT+: Pfizer is scolded by a U.K. trade group for remarks its CEO made about vaccination
After weeks of deliberation, Pfizer was scolded by a U.K. pharmaceutical industry trade group after…
STAT+: Pharmalittle: Some Republicans push to probe Pfizer over Covid-19 ‘mutations’; Warren urges FTC to probe pharma mergers
And so, another working week will soon draw to a close. Not a moment too…
STAT+: A bellwether for biosimilars: Why the new competition for Humira matters to pharma, payers, and patients
After months of anticipation, the first biosimilar version of Humira will become available next week…
STAT+: Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices
In her latest bid to address prescription drug prices, U.S. Sen. Elizabeth Warren (D-Mass.) is…
STAT+: Pharmalittle: Strange bedfellows lobby for Medicare coverage of obesity drugs; FDA working with WHO to probe cough syrups
Hello, everyone, and how are you this morning? We are doing just fine, thank you,…
STAT+: Novartis and Lilly turn to nonprofit, instead of FDA, to resolve dispute over drug ad
In a rare move, the Better Business Bureau National Programs settled a dispute between two…
STAT+: Pharmalittle: Merck ends late-stage trial for Keytruda in prostate cancer; doctor group says 60 Minutes segment on Wegovy was an ad
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Novartis is fined by Belgian regulators for anticompetitive practices over an eye treatment
Belgian anti-trust regulators fined Novartis nearly $2.8 million for making misleading statements about a treatment…
STAT+: Doctors’ group complains that 60 Minutes segment on Wegovy was really just an ad
A physicians’ group has filed a complaint with the U.S. Food and Drug Administration alleging…
STAT+: Pharmalittle: Amazon adds $5 monthly generic drug subscription; PhRMA ends lobbying contract with brother of White House official
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Many pediatric drug study results were never posted to a U.S. government database
Amid ongoing controversy over clinical trial transparency, a new analysis found that results of 43…
STAT+: Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity
In an unexpected move, the U.S. Food and Drug Administration will continue to apply exclusive…
STAT+: Pharmalittle: Obesity guidelines cause backlash; Bayer is pushed to spin off its consumer health business
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FTC wants ‘pharma bro’ Martin Shkreli held in contempt for violating lifelong ban on working in pharma
The U.S. Federal Trade Commission asked a federal judge to hold “pharma bro” Martin Shkreli…
STAT+: Pharmalittle: FDA rejects Lilly application for Alzheimer’s drug; Sanofi offers a warranty for a medicine
And so, another working week will soon draw to a close. Not a moment too…
STAT+: ‘A cascade of failures’: FDA cites Indian drugmaker for numerous quality control problems
In a stunning rebuke, the U.S. Food and Drug Administration accused a drugmaker of a…
STAT+: Pallone pushes NIH and FDA to disclose steps being taken to ensure clinical trial results are reported
A Democratic lawmaker is demanding to know what steps the U.S. Food and Drug Administration…
STAT+: For only the second time, a big drugmaker offers a warranty on a medicine
In a bid to blunt competition and address rising drug costs, Sanofi is offering a…
STAT+: Will the European Union give vouchers to pharma to develop badly needed antibiotics?
Amid rising concern over antibiotic resistance, a battle is brewing in Europe over a proposal…
.jpg)
STAT+: Pharmalittle: India regulator finds 5% of drug samples are substandard; EMA claims new clinical trial registry is fixed
Hello, everyone, and how are you today? A steely gray sky is hovering this morning…
STAT+: Pharmalittle: HIV vaccine study is stopped early; Merck has a plan to combat carcinogen found in diabetes drugs
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Major purchasers predict expensive new therapies will keep driving drug price hikes
More than two dozen big buyers of prescription medicines expect that prices will rise by…
STAT+: Pfizer says it will widen access to hundreds of off-patent medicines in poor countries
In another bid to widen access to its medical products, Pfizer plans to provide roughly…
STAT+: Pharmalittle: Lilly and AbbVie exit U.K. drug-pricing program; J&J scales back Covid-19 vaccine production
Good morning, everyone, and welcome to another working week, which is only getting started on…
STAT+: Large health insurers lowered barriers to fair access to some drugs, analysis finds
Most of the largest health plans in the U.S. generally provide “fair access” to 19…
STAT+: Pharmalittle: Pharma prioritizes biologics over pills due to drug-pricing law; former Takeda employee accused of creating fake consulting firm
And so, another working week will soon draw to a close. Not a moment too…
STAT+: California is the latest state to sue drugmakers and PBMs over insulin pricing
The California attorney general has filed a lawsuit accusing several drugmakers and pharmacy benefit managers…
STAT+: Pharmalittle: HHS readying details for Medicare drug-price negotiations; doctors urge FDA to hold expert meeting before approving Alzheimer’s drug
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug
A physicians group is urging the Food and Drug Administration to hold an expert panel…
STAT+: Pharmalittle: Pfizer will not license generic Covid-19 pill in China; BioMarin signs outcomes-based deal in Germany for gene therapy
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
.jpg)
STAT+: Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
For the third time in less than a year, a group of lawmakers is urging…
STAT+: FDA scolds Sun Pharmaceutical for serious quality control problems at a key plant in India
Sun Pharmaceutical, one of the world’s largest generic drugmakers, was scolded by the U.S. Food…
STAT+: Pharmalittle: FDA increasingly pauses trials of experimental meds; FDA commish isn’t surprised by congressional report on Alzheimer’s drug
Rise and shine, another busy day is on the way. We can tell if only…
STAT+: Moderna plans to follow in Pfizer’s footsteps, charge up to $130 for Covid-19 vaccine in U.S.
Moderna disclosed Monday that it plans to price its Covid-19 vaccine at anywhere from $110…
STAT+: Pharmalittle: Pediatricians recommend obesity drugs for children; as JPM starts, industry execs have a gloomy financing outlook
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The FDA has approved a new Alzheimer’s drug, but wide access may depend on CMS easing restrictions
Now that the U.S. Food and Drug Administration has granted accelerated approval to the widely…
STAT+: Pharmalittle: Pfizer scaling back early-stage research into rare diseases; BioNTech and U.K. partner on cancer trials
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharma’s ambitious antibiotic venture fund makes another investment
For only the second time since launching nearly two years ago, the AMR Action Fund…
STAT+: Pharmalittle: New report gives glimpse into safety of an Alzheimer’s drug; Walgreens looks to dispense an abortion pill
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: ‘Stuck in a rut’: As debate flares over access to medicines, the future of voluntary licensing is up in the air
ANNECY, FRANCE — At first blush, the deal was hailed as a breakthrough. Last fall,…